Literature DB >> 28278729

Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Melanie T Rebechi1, Keith W Pratz1.   

Abstract

Acute Myeloid Leukemia with FLT3 ITD mutations are associated with a poor prognosis characterized by a higher relapse rate, shorter relapse free survival, and decreased likelihood of response to therapy at relapse. FLT3 ITD signaling drives cell proliferation and survival. FLT3 ITD AML disease progression is associated with cytogenetic evolution and acquired tyrosine kinase inhibitor (TKI) resistance suggesting a potential role of genomic instability. There is growing evidence demonstrating a relationship between FLT3 signaling and increased DNA damage, specifically through increased reactive oxygen species (ROS) resulting in double-strand breaks (DSB), as well as impaired DNA repair, involving deficiencies in the non-homologous end joining (NHEJ), alternative non-homologous end joining (ALT NHEJ) and homologous recombination (HR) pathways. The role of genomic instability in the pathogenesis of FLT3 ITD AML warrants further examination as it offers potential therapeutic targets.

Entities:  

Keywords:  AML; DNA repair; FLT3; genomic instability

Mesh:

Substances:

Year:  2017        PMID: 28278729      PMCID: PMC5478446          DOI: 10.1080/10428194.2017.1283031

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  92 in total

Review 1.  PARP inhibition: PARP1 and beyond.

Authors:  Michèle Rouleau; Anand Patel; Michael J Hendzel; Scott H Kaufmann; Guy G Poirier
Journal:  Nat Rev Cancer       Date:  2010-03-04       Impact factor: 60.716

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

Review 3.  The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway.

Authors:  Michael R Lieber
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

4.  Genetic steps of mammalian homologous repair with distinct mutagenic consequences.

Authors:  Jeremy M Stark; Andrew J Pierce; Jin Oh; Albert Pastink; Maria Jasin
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

5.  BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.

Authors:  Michal O Nowicki; Rafal Falinski; Mateusz Koptyra; Artur Slupianek; Tomasz Stoklosa; Ewa Gloc; Margaret Nieborowska-Skorska; Janusz Blasiak; Tomasz Skorski
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

Review 6.  The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.

Authors:  Seth A Wander; Mark J Levis; Amir T Fathi
Journal:  Ther Adv Hematol       Date:  2014-06

7.  PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways.

Authors:  L Chang; P H Graham; J Hao; J Ni; J Bucci; P J Cozzi; J H Kearsley; Y Li
Journal:  Cell Death Dis       Date:  2014-10-02       Impact factor: 8.469

8.  Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.

Authors:  Keith W Pratz; Brian D Koh; Anand G Patel; Karen S Flatten; Weijie Poh; James G Herman; Robert Dilley; Maria I Harrell; B Douglas Smith; Judith E Karp; Elizabeth M Swisher; Michael A McDevitt; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 13.801

9.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

Review 10.  The detection and implication of genome instability in cancer.

Authors:  Larissa Pikor; Kelsie Thu; Emily Vucic; Wan Lam
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

View more
  12 in total

1.  Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Authors:  Silvia Maifrede; Margaret Nieborowska-Skorska; Katherine Sullivan-Reed; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Bac Viet Le; Martyna Solecka; Zhaorui Lian; Elizaveta A Belyaeva; Alina Nersesyan; Marcin M Machnicki; Monika Toma; Nicolas Chatain; Malgorzata Rydzanicz; Huaqing Zhao; Jaroslav Jelinek; Katarzyna Piwocka; Tomasz Sliwinski; Tomasz Stoklosa; Rafal Ploski; Thomas Fischer; Stephen M Sykes; Steffen Koschmieder; Lars Bullinger; Peter Valent; Mariusz A Wasik; Jian Huang; Tomasz Skorski
Journal:  Blood       Date:  2018-05-21       Impact factor: 22.113

Review 2.  Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia.

Authors:  Garrett M Dancik; Ioannis F Voutsas; Spiros Vlahopoulos
Journal:  Mol Biol Rep       Date:  2022-01-14       Impact factor: 2.316

Review 3.  Telomere Length and Hematological Disorders: A Review.

Authors:  Beatriz Maria Dias Nogueira; Caio Bezerra Machado; Raquel Carvalho Montenegro; Maria Elisabete Amaral DE Moraes; Caroline Aquino Moreira-Nunes
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

4.  DNA damage in acute myeloid leukemia patients of Northern Mexico.

Authors:  Martha I Dávila-Rodríguez; Elva I Cortés-Gutiérrez; Roberto Hernández-Valdés; Karla Guzmán-Cortés; Rosa E De León-Cantú; Ricardo M Cerda-Flores; Enrique Báez-De la Fuente
Journal:  Eur J Histochem       Date:  2017-12-11       Impact factor: 3.188

Review 5.  E-26 Transformation-specific Related Gene Expression and Outcomes in Cytogenetically Normal Acute Myeloid Leukemia: A Meta-analysis.

Authors:  Jian-Fei Fang; Hai-Ning Yuan; Yong-Fei Song; Pei-Bei Sun; Xiao-Liang Zheng; Xiao-Ju Wang
Journal:  Chin Med J (Engl)       Date:  2017-06-20       Impact factor: 2.628

6.  Discovery of Oxazol-2-amine Derivatives as Potent Novel FLT3 Inhibitors.

Authors:  Hyo Jeong Kim; Hwani Ryu; Jie-Young Song; Sang-Gu Hwang; Shivakumar S Jalde; Hyun-Kyung Choi; Jiyeon Ahn
Journal:  Molecules       Date:  2020-11-05       Impact factor: 4.411

7.  Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma.

Authors:  Martina Magni; Chiara Paolizzi; Chiara Monfrini; Cristina Vella; Paolo Corradini; Cristiana Carniti
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

8.  Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.

Authors:  Antonia Cagnetta; Debora Soncini; Stefania Orecchioni; Giovanna Talarico; Paola Minetto; Fabio Guolo; Veronica Retali; Nicoletta Colombo; Enrico Carminati; Marino Clavio; Maurizio Miglino; Micaela Bergamaschi; Aimable Nahimana; Michel Duchosal; Katia Todoerti; Antonino Neri; Mario Passalacqua; Santina Bruzzone; Alessio Nencioni; Francesco Bertolini; Marco Gobbi; Roberto M Lemoli; Michele Cea
Journal:  Haematologica       Date:  2017-10-12       Impact factor: 9.941

9.  Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis.

Authors:  Minglei Yang; Jian Zhao; Tielong Liu; Xinghai Yang; Haifeng Wei; Wei Xu; Jianru Xiao
Journal:  Cancer Manag Res       Date:  2018-08-14       Impact factor: 3.989

Review 10.  Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence.

Authors:  Salihanur Darici; Hazem Alkhaldi; Gillian Horne; Heather G Jørgensen; Sandra Marmiroli; Xu Huang
Journal:  J Clin Med       Date:  2020-09-11       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.